Epigenomics AG – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
SummaryPharmaceuticals and Healthcare
Key Findings
Pharmaceuticals and Healthcare
Pharmaceuticals and Healthcare
Reasons To Buys
MarketLine
Key Highlights
Germany
Epigenomics is a holding company. Through its Epigenomics Inc. subsidiary, Co. is engaged as a molecular diagnostics company focusing on developing and commercializing of in vitro diagnostic (IVD) tests for the screening and diagnosis of cancer. Co.'s products are based on a proprietary technology platform, which utilizes a biological phenomenon called DNA methylation as a source for the discovery of disease-specific biomarkers. Co. develops and commercializes cancer diagnostic tests in colorectal cancer (CRC) and in lung cancer. Co.'s key product is Epi proColon®, a blood-based test for the early detection of CRC which utilizes its proprietary DNA methylation biomarker, Septin9.
MarketLine, a world-leading provider of commercial intelligence, has over 400 experienced analysts, consultants, and researchers with regional and sector expertise in market sizing, competitor tracking, socio and macro economics, and business drivers.
For more than 15 years MarketLine has supported the research needs of investment banks, corporations, professional services firms, and academia with a unique mix of company, industry, country, city and financial data for every major industry and marketplace.
MarketLine’ holistic business intelligence report collection includes:
Industry Intelligence
‒ Industry Profiles
‒ Market Forecasts
‒ Porter’s Five Forces Analysis
Company Intelligence
‒ Company Profiles
‒ SWOT Analysis
‒ Financial Deals
Country and City Intelligence
‒ Country and City Profiles
‒ PEST/PESTLE Analysis
‒ Socio and macro-economic indicators
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.